Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Relay Therapeutics, Inc.’s reported figures.
The source filing: Relay Therapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:15 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338056
FAQ
- What is Relay Therapeutics, Inc.'s EBIT?
- Relay Therapeutics, Inc. (RLAY) reported EBIT of -$90.82M in Q2 2026.
- How has Relay Therapeutics, Inc.'s EBIT changed year-over-year?
- Relay Therapeutics, Inc.'s EBIT decreased by 18.2% year-over-year, from -$76.85M to -$90.82M.
- What is the long-term trend for Relay Therapeutics, Inc.'s EBIT?
- Over 4 years (2021 to 2025), Relay Therapeutics, Inc.'s EBIT has grown at a -4.5% compound annual growth rate (CAGR), from -$364.7M to -$302.74M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Relay Therapeutics, Inc.'s ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude